

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ocumension Therapeutics**  
**歐康維視生物**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock code: 1477)**

**POSITIVE PROFIT ALERT**

This announcement is made by Ocumension Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary review of the unaudited consolidated management accounts of the Group for the year ended December 31, 2022 and assessment of the latest information currently available to the Board, the Group is expected to record: (i) a total revenue of approximately RMB155.0 million to RMB159.0 million for the year ended December 31, 2022, representing an increase of approximately 176% to 183% as compared to the total revenue of approximately RMB56.1 million for the year ended December 31, 2021; and (ii) a gross profit of approximately RMB100.0 million to RMB103.0 million for the year ended December 31, 2022, representing an increase of approximately 171% to 179% as compared to the gross profit of approximately RMB36.9 million for the year ended December 31, 2021. The increase in the total revenue and the gross profit in 2022 is mainly attributable to: (i) the commercialization of the Company’s Core Product (as defined under the Listing Rules), OT-401 (fluocinolone intravitreal implant, trade name: Youshiying® (優施瑩®)); (ii) the increase in the revenue generated from sales of ophthalmic products, including Ou Qin® and brimonidine tartrate eye drop, among others; and (iii) the increase in the revenue generated from the pharmaceutical products promotion services.

The information contained in this announcement is only a preliminary assessment made by the Board based on the consolidated management accounts of the Group and the information currently available to the Board, and such consolidated management accounts have not been audited by the Company’s auditors or reviewed by the audit committee of the Board. The Company is still in progress of finalizing the annual results of the Group for the year ended December 31, 2022, and such annual results may be subject to further adjustment(s) and may be different from the information contained in this announcement. Shareholders of the Company and potential investors are advised to read carefully the details of the financial information of the Group to be disclosed in the annual results announcement of the Company, which is expected to be published in March 2023.

**Shareholders and investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Ocumension Therapeutics**  
**Dr. Lian Yong CHEN**  
*Chairman and Non-executive Director*

Hong Kong, February 14, 2023

*As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive directors.*